Deciphera Pharmaceuticals, Inc. (DCPH): Price and Financial Metrics
DCPH Stock Summary
- DCPH's price/sales ratio is 61.89; that's higher than the P/S ratio of 95.19% of US stocks.
- DCPH's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 10% of US stocks.
- As for revenue growth, note that DCPH's revenue has grown 68.35% over the past 12 months; that beats the revenue growth of 92.52% of US companies in our set.
- Stocks that are quantitatively similar to DCPH, based on their financial statements, market capitalization, and price volatility, are RGLS, RMBS, FOLD, XLRN, and CLVS.
- Visit DCPH's SEC page to see the company's official filings. To visit the company's web site, go to www.deciphera.com.
DCPH Stock Price Chart Interactive Chart >
DCPH Price/Volume Stats
| Current price | $44.82 | 52-week high | $68.40 |
| Prev. close | $45.20 | 52-week low | $39.42 |
| Day low | $44.64 | Volume | 196,343 |
| Day high | $46.17 | Avg. volume | 433,390 |
| 50-day MA | $44.53 | Dividend yield | N/A |
| 200-day MA | $51.20 | Market Cap | 2.58B |
Deciphera Pharmaceuticals, Inc. (DCPH) Company Bio
Deciphera Pharmaceuticals LLC develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. Its product pipeline includes Altiratinib (DCC-2701), a MET/TIE2/VEGFR2/TRK kinase inhibitor; DCC-2618, a pan-KIT inhibitor; Rebastinib, a TIE2/VEGFR1 kinase inhibitor; and LY3009120 (DP-4978), a pan-RAF inhibitor. The company was founded in 2003 and is based in Waltham, Massachusetts.
Latest DCPH News From Around the Web
Below are the latest news stories about Deciphera Pharmaceuticals Inc that investors may wish to consider to help them evaluate DCPH as an investment opportunity.
Is DCPH Stock A Buy or Sell?Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […] |
China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)China NMPA approval follows 2020 U.S. FDA approval for the treatment of patients with fourth-line GIST QINLOCK demonstrated a significant improvement in progression-free survival and a clinically meaningful benefit in overall survival compared to placebo in the pivotal Phase 3 INVICTUS study QINLOCK approval is the third innovative oncology product approval Zai Lab received in the last 15 months SHANGHAI, SAN FRANCISCO and WALTHAM, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Zai Lab (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Deciphera Pharmaceuticals (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the China National Medical Products A... |
Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare ConferenceWALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 9, 2021 at 1:50 PM ET. The conference will be held in a virtual meeting format. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/ne |
Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare ConferenceWALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021 at 4:20 PM ET. The conference will be held in a virtual meeting format. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investo |
Broker Revenue Forecasts For Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Are Surging HigherDeciphera Pharmaceuticals, Inc. ( NASDAQ:DCPH ) shareholders will have a reason to smile today, with the analysts... |
DCPH Price Returns
| 1-mo | -3.01% |
| 3-mo | -10.65% |
| 6-mo | -29.41% |
| 1-year | -9.20% |
| 3-year | 84.98% |
| 5-year | N/A |
| YTD | -21.46% |
| 2020 | -8.31% |
| 2019 | 196.52% |
| 2018 | -7.41% |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching DCPH
Want to see what other sources are saying about Deciphera Pharmaceuticals Inc's financials and stock price? Try the links below:Deciphera Pharmaceuticals Inc (DCPH) Stock Price | Nasdaq
Deciphera Pharmaceuticals Inc (DCPH) Stock Quote, History and News - Yahoo Finance
Deciphera Pharmaceuticals Inc (DCPH) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...